Education

  • MD, New York Medical College, Valhalla, NY
  • General Surgery Residency, University of Wisconsin Hospital and Clinics, Madison, WI
  • Research Fellowship, Memorial Sloan Kettering Cancer Center, New York, NY
  • Clinical Fellowship, Memorial Sloan Kettering Cancer Center, New York, NY
  • MAS, University of California San Diego, San Diego, CA

Clinical Specialties

Dr. Kelly’s primary clinical practice includes the treatment of upper gastrointestinal malignancies, including gastric, pancreatic, and hepatobiliary cancers, as well as peritoneal surface malignancy, melanoma, and sarcoma. She is particularly interested in developing minimally invasive techniques for cancer surgery. Dr. Kelly’s primary clinical and research interest is gastric cancer. She is among the highest-volume gastric cancer surgeons in the country with over 10 year of experience, and has pioneered minimally-invasive surgical techniques for gastrectomy with comprehensive lymph node removal. Dr. Kelly also performs some operations with an open technique when necessary, and can perform additional procedures to treat liver cysts, chronic pancreatitis, and gallbladder disease. Dr. Kelly is board-certified in Complex General Surgical Oncology and General Surgery.

Research Interests

Dr. Kelly is a clinical and translational researcher. She is a Nationally-recognized expert in gastric cancer treatment and much of her research is aimed to improve the quality of gastric cancer surgery as it is performed across the U.S.  She is also involved in the development and conduct of clinical trials. Dr. Kelly is an active member of the Alliance for Clinical Trials in Oncology, the Eastern Cooperative Oncology Group (ECOG), the American College of Surgeons, the Society of Surgical Oncology, and the American Society of Clinical Oncology.

Recent Publications

  • Survival Outcomes Between Minimally Invasive and Open Gastrectomy in Early and Locally Advanced Gastric Adenocarcinoma in a Western Center.
    Kalavacherla S, Neel N, Jagadeesh V, Bouvet M, Lowy A, Horgan S, Kelly KJ, Mehtsun WT
    J Gastrointest Cancer 2025 Feb 20; 56(1): 68
    [PubMed ID: 39979489]

  • Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
    Hodan R, Gupta S, Weiss JM, Axell L, Burke CA, Chen LM, Chung DC, Clayback KM, Felder S, Foda Z, Giardiello FM, Grady W, Gustafson S, Hagemann A, Hall MJ, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz AJ, Prats MM, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder NJ, Shibata D, Stanich PP, Swanson BJ, Szymaniak BM, Welborn J, Wiesner GL, Yurgelun MB, Dwyer M, Darlow S, Diwan Z
    J Natl Compr Canc Netw 2024 Dec; 22(10): 695-711
    [PubMed ID: 39689429]

  • Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.
    Weitz J, Nishizaki D, Liau J, Patel J, Ng I, Sun S, Ramms D, Zou J, Wishart B, Rull J, Baumgartner J, Kelly K, White R, Veerapong J, Hosseini M, Patel H, Botta G, Gutkind JS, Tiriac H, Kato S, Lowy AM
    J Clin Oncol 2025 Feb 20; 43(6): 705-715
    [PubMed ID: 39413348]

  • ASO Visual Abstract: Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.
    Cox KE, Turner MA, Lwin TM, Amirfakhri S, Kelly KJ, Hosseini M, Ghosh P, Obonyo M, Hoffman RM, Yazaki PJ, Bouvet M
    Ann Surg Oncol 2024 Jul 16;
    [PubMed ID: 39012463]

  • Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.
    Cox KE, Turner MA, Lwin TM, Amirfakhri S, Kelly KJ, Hosseini M, Ghosh P, Obonyo M, Hoffman RM, Yazaki PJ, Bouvet M
    Ann Surg Oncol 2024 Sep; 31(9): 6291-6299
    [PubMed ID: 38888861]

All Publications on PubMed